Semaglutide reduces risk of MACE consistently across baseline triglyceride levels in patients with type 2 diabetes: Post Hoc Analyses of SUSTAIN 6 and PIONEER 6 trials.
Subodh VermaJens-Peter DavidLawrence A LeiterMarie Mide MichelsenSøren RasmussenDeepak L BhattPublished in: Diabetes, obesity & metabolism (2023)
Keyphrases